BridgeBio Oncology Therapeutics Inc.
NASDAQ:BBOTBiotechnology
-$0.03 today
- Market cap
- $144.85M
- Beta
- 0.29
- P/E (TTM)
- -1.5
- EPS (TTM)
- -$4.95
Volume 0.58M
Average 0.37M
BBOT Gross Profit
Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.
BridgeBio Oncology Therapeutics Inc.NASDAQ: BBOT
Gross Profit · Q1 FY2026 · quarter ended Mar 2026
Gross profit turns negative
Q1 FY2026 gross profit was -$186K, compared with $0 a year earlier. Trailing-twelve-month gross profit was -$186K.
Context
- Gross profit increased in 0 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly gross profit holds near -$186K or moves back toward the trailing-twelve-month quarterly average of -$46.5K.
Sources:Income StatementText generated from reported figures; not investment advice.
Gross Profit history
USD · from the income statement
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Gross Profit | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Gross Profit vs competitors
How BBOT compares with its peers on the latest reported figures
- Peers report in different currencies, so gross profit is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -19.2% is the 7th highest of 9, against a peer median of +123.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Aug 2026 | $607.18M USD | +545.5% | — | 86.5% | |
| LTM Mar 2026 | $270.54M USD | +582.2% | — | 116.4% | |
| LTM Mar 2026 | $174.02M USD | +146.5% | — | 84.9% | |
| LTM Mar 2026 | $126.24M USD | +53.2% | +19.7% | 89.9% | |
SEPNSepterna, Inc. | LTM Sep 2026 | $76.97M USD | +249.1% | — | 79.9% |
| LTM Jun 2026 | $45.46M USD | -54.8% | — | 43.3% | |
| LTM Sep 2026 | $0 USD | +100.0% | — | — | |
BBOTBridgeBio Oncology Therapeutics Inc. | LTM Mar 2026 | -$186K USD | -19.2% | — | — |
| LTM Sep 2026 | -$942K USD | -101.4% | +34.2% | — | |
| LTM Mar 2026 | -CHF 14.56M CHF | — | — | 2889.4% | |
| Peer median (excluding BBOT) | — | +123.3% | +27.0% | 86.5% | |
Competitors are the stored peer set for BBOT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 0 | 0 | 56.29M | 73.11M | 121.2M |
| Selling, General & Admin | 43.36K | 3.52K | 8.49M | 7.76M | 24.62M |
| Operating Expenses | 43.36K | 3.52K | 64.77M | 80.86M | 145.82M |
| Depreciation & Amortization | 74.33K | 3.52K | 92K | 208K | 610K |
| EBITDA | (43.36K) | (3.52K) | (64.68M) | (80.66M) | (145.21M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (43.36K) | (3.52K) | (64.77M) | (80.86M) | (145.82M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 0 | 72K | 8.46M | 11.34M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 0 | 0 | 72K | 8.18M | 11.78M |
| Income Before Tax | (43.36K) | (3.52K) | (64.7M) | (74.28M) | (134.04M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (43.36K) | (3.52K) | (64.7M) | (74.28M) | (134.04M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (0.00) | 0.00 | (3.16) | 0.46 | (4.30) |
| EPS (Diluted) | (0.00) | (0.00) | (3.16) | 0.46 | (4.30) |
| Weighted Avg Shares | 20.49M | 20.49M | 20.49M | 16.64M | 31.14M |
| Weighted Avg Shares (Diluted) | 20.49M | 20.49M | 20.49M | 16.64M | 31.14M |
BridgeBio Oncology Therapeutics Inc.
NASDAQ:BBOT
Intrinsic Alpha fair value
Locked
Current Price
$1.81
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.